重组带状疱疹疫苗对自体干细胞移植后带状疱疹发生率的影响:一项随机临床试验
这项3期随机观察者盲法研究在28个国家167个中心纳入1846例近期接受自体造血干细胞移植的成人,比较2剂重组带状疱疹疫苗与安慰剂的疗效。中位随访21个月,疫苗组带状疱疹发生率30/1000人年,安慰剂组94/1000人年,疫苗效力68.2%,不良事件两组相似。
要点
- 自体造血干细胞移植后接种2剂重组带状疱疹疫苗可显著降低带状疱疹发生率。
- 疫苗组带状疱疹发生率30/1000人年 vs 安慰剂组94/1000人年,疫苗效力68.2%。
- 注射部位反应疫苗组86% vs 安慰剂组10%,严重不良事件两组相似。
核心结论
- 在自体造血干细胞移植成人中,2剂重组带状疱疹疫苗较安慰剂显著降低中位随访21个月内的带状疱疹发生率。
研究设计与样本
- 3期随机观察者盲法研究,2012年7月13日至2017年2月1日在28个国家167个中心开展。
- 纳入1846例18岁及以上近期接受自体造血干细胞移植的患者,随机接受2剂重组带状疱疹疫苗(n=922)或安慰剂(n=924),首剂于移植后50至70天给予,第二剂于其后1至2个月给予。
主要发现
- 中位随访21个月,疫苗组49例和安慰剂组135例确认至少1次带状疱疹发作,发生率分别为30/1000人年和94/1000人年,发生率比(IRR)0.32(95%CI 0.22-0.44;P<.001),相当于疫苗效力68.2%。
- 带状疱疹后神经痛:疫苗组n=1 vs 安慰剂组n=9,IRR 0.1(95%CI 0.00-0.78;P=.02)。
- 其他预设带状疱疹相关并发症:疫苗组n=3 vs 安慰剂组n=13,IRR 0.22(95%CI 0.04-0.81;P=.02)。
- 严重最差带状疱疹相关疼痛持续时间:疫苗组892.0天 vs 安慰剂组6275.0天,风险比0.62(95%CI 0.42-0.89;P=.01)。
- 注射部位反应疫苗组86% vs 安慰剂组10%,疼痛最常见,疫苗组84%(3级11%);非 solicited 和严重不良事件、潜在免疫介导疾病及基础疾病复发在各时间点两组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. OBJECTIVE: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT. INTERVENTIONS: Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. MAIN OUTCOMES AND MEASURES: The primary end point was occurrence of confirmed herpes zoster cases. RESULTS: Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P = .02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P = .02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P = .01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points. CONCLUSIONS AND RELEVANCE: Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01610414.
引用
- Bastidas A, de la Serna J, El Idrissi M, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019. PMID: 31287523. doi:10.1001/jama.2019.9053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。